Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post-marketing study of cilostazol: study to confirm efficacy in preventing recurrent cerebral infarction in comparison with aspirin.

Next Previous
Trial Profile

Post-marketing study of cilostazol: study to confirm efficacy in preventing recurrent cerebral infarction in comparison with aspirin.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilostazol (Primary) ; Aspirin
  • Indications Embolism and thrombosis; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CSPS-II
  • Sponsors Otsuka Pharmaceutical

Most Recent Events

  • 13 May 2016 Status changed from active, no longer recruiting to completed.
  • 03 Mar 2010 Results were presented in a late-breaking science session at the American Stroke Association's International Stroke Conference, according to an Otsuka Pharmaceutical media release (9110055) and an American Stroke Association media release (9109952).
  • 23 Apr 2008 Changed patient number from 2600 to 2800. Update from ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top